SCHEMBL1542345

SCHEMBL1542345

C#Cc1ccc(NC(=O)NC)cc1

nearest known ligand 0.67

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 4/20 0.58
CYP2C9 P11712 2/20 0.54
KMT2A Q03164 3/20 0.51
POLB P06746 2/20 0.47
SAE1 Q9UBE0 1/20 0.46
UBA2 Q9UBT2 1/20 0.46
RAB9A P51151 4/20 0.46
SMN1; SMN2 Q16637 3/20 0.46
KDM4E B2RXH2 3/20 0.46
MEN1 O00255 2/20 0.46
HPGD P15428 2/20 0.46
CYP2C19 P33261 1/20 0.46
RECQL P46063 1/20 0.44
MAPT P10636 4/20 0.43
LMNA P02545 2/20 0.43
TSHR P16473 1/20 0.43
HTT P42858 1/20 0.43
NLRP3 Q96P20 1/20 0.43
PKM P14618 1/20 0.42
MAPK1 P28482 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4748577 0.88 CYP2C9 (0.56) ALDH1A1CYP2C9KMT2APOLBSAE1
SCHEMBL10155599 0.83 ALDH1A1 (0.78) ALDH1A1KMT2APOLBSAE1UBA2
SCHEMBL10586455 0.82 ALDH1A1 (0.60) ALDH1A1KMT2APOLBSAE1UBA2
SCHEMBL6125249 0.81 SAE1 (0.69) ALDH1A1KMT2APOLBSAE1UBA2
SCHEMBL17424508 0.81 CYP2C9 (0.67) ALDH1A1CYP2C9KMT2APOLBRAB9A
SCHEMBL12846187 0.80 CA12 (0.55) ALDH1A1CYP2C9KMT2APOLBRAB9A
SCHEMBL474661 0.80 KMT2A (0.70) ALDH1A1KMT2APOLBRAB9ASMN1; SMN2
SCHEMBL12049693 0.79 IDH1 (0.54) ALDH1A1CYP2C9KMT2APOLBRAB9A
SCHEMBL9771269 0.78 KMT2A (0.68) ALDH1A1KMT2APOLBRAB9ASMN1; SMN2
SCHEMBL8319331 0.78 CYP2C9 (0.50) ALDH1A1CYP2C9KMT2ARAB9ASMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8273773-B2 Heterocyclic antiviral compounds ROCHE PALO ALTO LLC (US) 2012-09-25 US disclosed
EP-2307372-B1 HETEROCYCLIC ANTIVIRAL COMPOUNDS HOFFMANN LA ROCHE (CH) 2012-04-25 EP disclosed
EP-2307372-A1 HETEROCYCLIC ANTIVIRAL COMPOUNDS F. Hoffmann-La Roche AG (CH) 2011-04-13 EP disclosed
WO-2010010017-A1 HETEROCYCLIC ANTIVIRAL COMPOUNDS F. HOFFMANN-LA ROCHE AG (CH) 2010-01-28 WO disclosed
US-20100021423-A1 Heterocyclic antiviral compounds ROCHE PALO ALTO LLC 2010-01-28 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100021423-A1 Heterocyclic antiviral compounds POLR2A, RRM2B, RRP1B ALDH1A1 1136/4885CYP2C9 146/4885KMT2A 2398/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.